Starting GLP-1 for Weight Loss: My Honest Guide for 2026

If you are reading this, something has been bothering you. The scale hasn’t moved the way you wanted. Or it did, then came back. Or you’ve been watching friends see weight loss results with a weekly shot and you cannot tell if they got lucky or got something you should be looking into too.

Here is the editorial take: GLP-1 is one of the most significant advances in obesity medicine in recent decades. The clinical research on the brand-name formulations is strong. And access has become easier than it used to be — a licensed telehealth clinician can review your intake online instead of requiring weeks of insurance approvals.

What follows is independent editorial research on the category — what the trials show, who it works for, and how readers most commonly access it today.

First, Let Me Guess Why You Are Here

Important: The clinical trial results cited in this article (STEP, SURMOUNT) studied the FDA-approved branded medications (Wegovy®, Ozempic®, Mounjaro®, Zepbound®). These results do not apply to and cannot be attributed to compounded semaglutide or compounded tirzepatide. Compounded medications are not FDA-approved. Always talk to a licensed physician.

If any of that sounds like you, stick with me. By the end of this you will know what GLP-1 actually is, what the research shows, and exactly how to tell if it is the right next step for you.

What GLP-1 Really Is, Made Simple

GLP-1 stands for glucagon-like peptide-1. It is a hormone your own body already makes. Every time you eat, your gut releases a little GLP-1. It tells your brain you are full. It helps your body handle blood sugar. It slows your stomach down so food sits longer.

The problem for a lot of people is that this signal is too quiet. You eat, and the “I am full” message never quite lands. So you keep eating, or you get hungry again two hours later.

GLP-1 medications copy that hormone. They make the signal louder and make it last longer. In published trials and patient-reported forums, common experiences people describe include:

• Reduced “food noise” — the constant background thought about what to eat next tends to fade.
• Smaller portions feeling satisfying without forcing it.
• Less mental negotiation around food.

Individual experiences vary. The biology is well-understood: the medication quiets appetite signals in the brain and slows stomach emptying. It is not willpower-in-a-syringe. It is a body that finally receives the “you are full” message more clearly.

Here are the names you keep hearing, decoded:

• Semaglutide is the drug. Ozempic and Wegovy are the two brand names for it (Ozempic is for type 2 diabetes, Wegovy is for weight loss — same molecule).
• Tirzepatide is a newer drug. Mounjaro and Zepbound are its brand names (same split — Mounjaro for diabetes, Zepbound for weight loss).
• Compounded semaglutide and compounded tirzepatide are custom-mixed versions made by licensed compounding pharmacies. They are not FDA-approved. They became common during the brand-name shortages in 2023 and 2024 and are how most telehealth platforms serve patients today.

Brand-Name vs. Compounded: The Honest Version

Here is the practical truth: if insurance will cover Wegovy or Zepbound, take that route. For most people it will not — insurance coverage for weight-loss medications remains patchy, prior authorization takes weeks, and the out-of-pocket price on brand-name is steep. That is why compounded GLP-1 through a licensed telehealth provider is now the path most adults actually end up using. Both routes need a licensed prescriber — you are not skipping the doctor, you are just meeting them through a screen.

Semaglutide vs. Tirzepatide: What the Research Says

Two big trials changed this whole conversation. If you remember nothing else, remember these names.

STEP 1 (semaglutide)

The STEP 1 trial tested Wegovy® (the FDA-approved branded semaglutide) in nearly 2,000 adults with obesity. Over 68 weeks, people on Wegovy® (semaglutide brand) lost an average of about 15% of their body weight. The placebo group lost around 2% ^[1]. That is a level of weight loss researchers had never before seen from a weekly shot.

SURMOUNT-1 (tirzepatide)

The SURMOUNT-1 trial tested Zepbound® (the FDA-approved branded tirzepatide) over 72 weeks. The top-dose group lost an average of about 22.5% of their body weight ^[2]. That is in the same ballpark as some bariatric surgeries. In plain words: tirzepatide, in the trial, outperformed semaglutide.

STEP 4 (what happens when you stop)

This one matters more than people realize. The STEP 4 trial showed that people who kept taking Wegovy® (semaglutide brand) kept losing or held the loss, while people who stopped Wegovy® tended to regain a big chunk of it ^[3]. GLP-1 is not a 90-day reset. It is closer to a long-term tool, the way a blood pressure medication is.

My honest read on the research: the effect is real, it is large, and it is well-studied. Tirzepatide is the bigger lever. Semaglutide has the longer track record. Both only work as long as you take them.

What to Expect While Your Body Adjusts

Most people experience some mild stomach stuff the first few weeks — nausea or fullness, especially on dose-up days ^[1]. In the trials, this faded for the majority of patients as the body adjusted. A good telehealth provider paces the dose step-ups to minimize it.

A licensed clinician will also screen you for the health history questions that matter (pancreatic, thyroid, family history) before you ever see a dose. That screening is the safety net — the reason the clinical model matters more than the checkout process.

My Honest Take: Who GLP-1 Works For

After all the reading, here is who I think genuinely benefits:

For readers who fit the clinical profile, the research case is real and access is more available than it has been historically. A licensed telehealth clinician can review an intake form, screen your medical history, and determine whether GLP-1 is appropriate for you.